Covishield Vaccine Case: AstraZeneca expresses 'sympathy' for those who lost loved ones

Covishield Vaccine Case: AstraZeneca expresses 'sympathy' for those who lost loved ones

AstraZeneca Reaffirms Commitment to Patient Safety

AstraZeneca Reaffirms Commitment to Patient Safety

Amid the recent concerns regarding potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant has reaffirmed its dedication to patient safety. It underscored the vaccine's overall safety profile while prioritizing the well-being of recipients.

An AstraZeneca spokesperson stated, "Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is paramount, and we are committed to addressing any concerns."

The pharmaceutical company maintained that the vaccine's safety and efficacy are consistently supported by extensive clinical trial data and real-world evidence. Regulatory agencies worldwide continue to state that the benefits of vaccination are greater than the risks of these extremely rare side effects.

Earlier this week, AstraZeneca admitted that its Covid-19 vaccine can cause a rare side effect called Thrombosis with Thrombocytopenia Syndrome (TTS). This acknowledgment coincides with ongoing legal proceedings initiated by victims and their families.

AstraZeneca collaborated with the University of Oxford to develop the vaccine and is currently involved in legal proceedings initiated by victims and their families. One particular case includes Jamie Scott, a father of two, who took legal action after experiencing a blood clot that rendered him unable to work. Scott claims that following his vaccination in April 2021, he developed a "blood clot and a bleed on his brain," resulting in a lasting brain injury.

Zurück zum Blog

Hinterlasse einen Kommentar

Bitte beachte, dass Kommentare vor der Veröffentlichung freigegeben werden müssen.